Biotech Co. Wants $881M Cannabinoid IP Fight Arbitrated
Biotech company Amyris Inc. says cannabinoid manufacturer Lavvan Inc. should be forced to arbitrate its claims in an $881 million trade secrets lawsuit between the companies, or the suit should be...To view the full article, register now.
Already a subscriber? Click here to view full article